Dr Reddys Laboratories
Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established itself as a leader in the development and manufacturing of a wide range of generic medications, active pharmaceutical ingredients (APIs), and proprietary products. With a strong presence in markets across North America, Europe, and Asia, Dr. Reddy's is committed to providing affordable healthcare solutions. The company’s core offerings include generic formulations, biosimilars, and over-the-counter products, distinguished by their quality and innovation. Dr. Reddy's has achieved significant milestones, including numerous product launches and strategic partnerships, solidifying its market position. Recognised for its commitment to sustainability and patient-centric approach, Dr. Reddy's Laboratories continues to make strides in enhancing global health outcomes.
DitchCarbon Score
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr Reddys Laboratories's score of 66 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dr Reddys Laboratories's reported carbon emissions
In 2023, Dr. Reddy's Laboratories, headquartered in India, reported carbon emissions of approximately 214,257,000 kg CO2e for Scope 1, 137,627,000 kg CO2e for Scope 2, and 921,055,000 kg CO2e for Scope 3. This reflects a significant commitment to reducing their carbon footprint, with a target of achieving a 55% reduction in total carbon emissions by 2030, using 2018 as the base year. The company has set specific reduction targets through the Science Based Targets initiative (SBTi), aiming for a 50.2% reduction in Scope 1 and 2 emissions per million USD revenue by FY2031, which translates to a 25% absolute reduction. Additionally, Dr. Reddy's commits to a 12.3% reduction in absolute Scope 3 emissions within the same timeframe. These targets align with the global goal of limiting temperature rise to well below 2°C. Dr. Reddy's Laboratories is actively working towards these ambitious goals, demonstrating a strong commitment to sustainability and climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 349,108,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 195,287,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 345,407,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dr Reddys Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
